What we’re proposing
PHARMAC is seeking feedback on a proposal to list an obstetrics and gynaecology medical device in Part III of the Section H of the Pharmaceutical Schedule from 1 May 2020 through a provisional agreement with Ultramedix Australasia Limited (“Ultramedix”).
Consultation closes at 4pm on Monday 2 March 2020 and feedback can be emailed to firstname.lastname@example.org.
What would the effect be?
From 1 May 2020, Ultramedix’s obstetrics and gynaecology device would be listed under the proposed national agreement (“Agreement”) that all DHBs may purchase under, subject to consultation and approval by PHARMAC’s Board or delegate.
The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of obstetrics and gynaecology devices.
The Agreement would supersede any existing DHB contract with the supplier for the device listed in the Agreement. Any device listed in the PHARMAC Agreement and purchased by the DHB would be at the price, terms and conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.
Ultramedix would provide appropriate training and education services that would be tailored to the individual needs of the DHBs, in formats and at times as required by the DHBs.
Pricing for the medical device in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- All DHB clinical staff including but not limited to:
- Obstetricians and gynaecologists
- Clinical/Biomedical Engineers
- Sterile services staff
- Outpatient clinic staff
- Theatre and perioperative staff
- Surgical, speciality units, gynaecology and general ward staff
- Delivery suite staff
- Procurement Officers
- Suppliers and Wholesalers
About the medical devices
Obstetrics and gynaecology products
This category includes all equipment and consumables used in the obstetrics and gynaecology specialities. Products used in delivery suites and by midwives on the wards are included. Gynaecology is the specialty that treats conditions related to female reproductive organs. A small number of devices related to fertility and sterility may be listed as some limited assisted reproduction services are provided by a small number of DHB Hospitals. However most funded services are provided by private clinics are therefore out of scope for PHARMAC.
Details about our proposal
PHARMAC has entered into a provisional Agreement with Ultramedix for the supply of the PartoSure test kit.
Pricing for these products has been made available to appropriate DHB personnel.
To provide feedback
Send us an email: email@example.com by 4pm on Monday 2 March 2019.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.
Last updated: 10 February 2020